The global electroencephalography devices market size was valued at over USD 829.3 million in 2018 and is anticipated to expand at a CAGR of 8.7% over the forecast period. Increasing prevalence of neurological disorders and rising awareness about them are major factors contributing to the growth. High incidence of Alzheimer’s, epilepsy, dementia, multiple sclerosis, Parkinson’s disease, and stroke has been key in the rising adoption of electroencephalography (EEG) devices. According to the data from Alzheimer's Association, almost 5.7 million Americans were suffering from Alzheimer’s in 2018. It further estimates that by 2050, over half the population over the age of 65 will suffer from dementia.
According to the data from the ALS Association, over 5,000 Americans are diagnosed with Amyotrophic Lateral Sclerosis (ALS) each year and these figures are expected to double in near future. Estimates from the National Vital Statistics Report compiled by the Centers for Disease Control and Prevention (CDC) indicate that stroke was the fifth leading cause of mortality in U.S. Data from the same source indicates that the average years of potential life lost under 75 years of age due to cerebrovascular diseases was 187.1 in U.S. These facts are indicative of rising prevalence of the disease, requiring constant monitoring and treatment, propelling demand for EEG systems.
According to the Alzheimer’s Disease International, South East Asia is expected to witness a 226% rise in Alzheimer’s cases whereas the African region is anticipated to witness a rise of 345%, and the Americas region is expected to see a rise of 248%. Data from the same source also indicate that by 2050, the global number of Alzheimer’s disease patients will reach over 106.23 million. Rising geriatric population globally owing to enhanced healthcare systems is therefore facilitating increased R&D in the field of neuroscience. Takeda’s collaboration with Denali Therapeutics focused on Alzheimer’s and Parkinson’s and Biogen’s tie-up with Pfizer for the development of cognitive drugs for schizophrenia are anticipated to positively impact market growth during the forecast period.
Rising R&D investments by manufacturers to provide advanced brain monitoring devices is another major factor significantly contributing to the growth of the electroencephalography systems market. For instance, Natus Medical, Inc. invested around USD 33.4 million for R&D in the 2016. The companies are investing in R&D to improve the existing products and to develop new ones to cater to the increasing demand for advanced devices.
On the basis of product, the electroencephalography devices market is segmented into 32-channel EEG, 25-channel EEG, 8-channel EEG,40-channel EEG, 21-channel EEG, and multichannel EEG. In 2018, 32-channel EEG was the largest revenue grossing segment and is also projected to maintain its dominance during the forecast period. Technological advancement in 32-channel EEG products and its high adoption by healthcare professional are the major factors driving growth.
In terms of revenue, the 32-channel EEG segment is followed by 25-channel EEG & 40-channel EEG segmentsin 2018. These segments are expected to showcase significant CAGR during the forecast period.Products offered by companies such as Neurofax EEG-1200 Diagnostic and Monitoring Platform by Nihon Kohden Corporation are expected to gain popularity over the next few years.
Multi-channel EEG systems are used to record electrical activities in the brain to diagnose neurological disorders, strokes, and other brain disorders, and detect tumors. The companies offering these products are Compumedics Limited (Neuvo 64-512 Channel LTM EEG, Grael LT EEG System, Grael 4K-EEG), Natus Medical Inc. (NicoletOne, Xltek EEG Systems) among others. This segment is anticipated to exhibit significant growth over the forecast period.
On the basis of type, the market is segmented into standalone devices and portable devices. Standalone devices accounted for the major market share in terms of revenuein 2018. The standalone devices are the most commonly used type of EEGs. The high application of these devices in critical care is a key factor contributing to its high revenue share.
Standalone EEG systems are systems that are fixed or implanted at a particular place. Such systems are used mainly in hospital settings and consists of hardware and software solutions that allow physicians to interpret results efficiently. EEG devices are used to record electrical activities in the brain. With an increase in the number of neurological diseases like tumors, cerebral palsy, strokes, and other brain-related disorders, a huge number of patients have been admitted for treatment in hospital settings. This has largely contributed to the surge of standalone devices that are used in such settings.
Portable EEG devices are transportable in nature and can deduce similar results as those done by standalone devices. These devices are often used in ambulatory services and other paramedic settings where electrical activity of the brain has to be measured in order to understand the condition of the patient. Portable systems are also used in homecare settings to deal with comatose patients and patients suffering from other neurological disorders.
Portable devices segment is expected to exhibit the highest CAGR during the forecast period. Major factor contributing to the growth are increasing focus of manufacturers on technological advancements, such as portability, light weight, and simultaneous raw data acquisition. Also, rising demand of portable devices for clinical practice and outdoor investigation is projected to bode well for the segment growth.
Hospitals led the overall market in 2018 owing to the growing number of patients suffering from traumatic brain injuries, epilepsy, and other neurological disorders. In addition, increasing focus on development of healthcare infrastructure in developing countries of Asia Pacific and Africa propels the segment growth.
Hospitals held the highest market share owing to increasing admissions of patients suffering from traumatic brain injuries, epilepsy, and other neurological disorders. Hospitals are primary end users of the ECG devices because of their need to record the rhythm and electrical activity and evaluate the results in detail for clinical and research purposes. Thus, this segment dominated the market in 2018, owing to the high patient turnaround and frequent readmissions.
Diagnostic centers segment is expected to witness fastest growth during the study period, due to the growing awareness regarding neurodegenerative disorders. The rising awareness among people leads to demand for advanced EEG products for diseases diagnosis and prevention. The demand for advanced diagnostics products is high in developed countries like U.S. and Germany, due to highly developed healthcare infrastructure in these countries.
The others end use segment consists of neurological centers, clinical research organizations, and academic research organizations.Neurological centers specifically cater to those patients suffering from neurological diseases and usually operate in collaborations with hospitals & companies. With an increase in the number of neurological disorders, there is a huge demand for diagnosis & treatment at such centers that provide patients with specialized care & management of the disease.
North America led the EEG devices market in 2018 followed by Europe and Asia Pacific. Rising prevalence of various sleep and neurodegenerative disorders and accessibility to insurance are major factors contributing to the regional growth. Moreover, the presence of highly developed healthcare infrastructure and strong distribution and sales network of leading vendors in this region are anticipated to drive the growth.
Favorable reimbursement policies in U.S. have surged the usage of these systems for diagnosis of neurological disorders. Presence of government organizations such as National Institute of Neurological Disorders and Stroke (NINDS) that provide funding for R&D activities applicable in treatment of brain nervous disorders contributed to the dominance of the regional market.
Europe is expected to showcase steady growth over the forecast period owing to the presence of well-established healthcare system. Establishment of various nonprofit organizations such as the European Multiple Sclerosis Platform (EMSP) is expected to further boost the market. According to the EMSP, approximately 9 million people in Europe are affected by neurodegenerative diseases. This organization encourages research and data collection related to multiple sclerosis and focuses on spreading awareness regarding the same in Europe and other regions, thus, boosting the growth.
Asia Pacific is estimated to expand at the highest CAGR during the forecast period because of increasing geriatric population in this region. Also, untapped opportunities along with rapidly developing healthcare infrastructure in countries such as India and China is driving the market growth.
Some of the key market players are Natus Medical, Inc.; Electrical Geodesics, Inc.; Medtronic; NeuroWave Systems, Inc.; Compumedics Ltd.; Noraxon U.S.A., Inc.; Cadwell Laboratories, Inc., and Nihon Kohden America, Inc.
The EEG systems market is a blend of large, well-established public companies and private firms. These include Compumedics Ltd.; Natus Medical, Inc.; Elmiko Medical; Electrical Geodesics, Inc.; Medtronic; NeuroWave Systems, Inc.; Cadwell Industries, Inc.; and Nihon Kohden Corporation.
Companies such as Electrical Geodesics, Inc.; Medtronic; and Cadwell Industries, Inc. have an extensive product portfolio coupled with strong regional presence. Existence of a broad range of product portfolio and new product development are some of the major factors contributing to the growth of the companies.
The major companies are undertaking various organic as well as inorganic strategies such as new product development, collaborations, acquisitions, mergers, and regional expansion for serving the unmet needs of their customers. For instance, in July 2016, Compumedics Ltd and Bestmed announced a new 3-year distribution agreement for Compumedics’ neurodiagnostic and monitoring systems across the South and Central China.
Base year for estimation
Actual estimates/Historical data
2015 - 2017
2019 - 2026
Revenue in USD Million & CAGR from 2019 to 2026
North America, Europe, Asia Pacific, Latin America & MEA
U.S., Canada, U.K., Germany, France, Italy, Spain, Russia, Japan, India, China, South Korea, Singapore, Australia, Argentina, Brazil, Mexico, South Africa, Saudi Arabia, UAE
Revenue forecast, company share, competitive landscape, growth factors and trends
15% free customization scope (equivalent to 5 analyst working days)
If you need specific information, which is not currently within the scope of the report, we will provide it to you as a part of customization
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2014 to 2026. For the purpose of this study, Grand View Research has segmented the global electroencephalography devices market report on the basis of product, type, end use, and region:
Product Outlook (Revenue, USD Million, 2015 - 2026)
25 channel EEG
Type Outlook (Revenue, USD Million, 2015 - 2026)
End Use Outlook (Revenue, USD Million, 2015 - 2026)
Regional Outlook (Revenue, USD Million, 2015 - 2026)
b. The global electroencephalography devices market size was estimated at USD 888.9 million in 2019 and is expected to reach USD 956.1 million in 2020.
b. The global electroencephalography devices market is expected to grow at a compound annual growth rate of 8.7% from 2019 to 2026 to reach USD 1.6 billion by 2026.
b. North America dominated the electroencephalography devices market with a share of 39.9% in 2019. This is attributable to the rising prevalence of various sleep and neurodegenerative disorders and accessibility to insurance.
b. Some key players operating in the electroencephalography devices market include Natus Medical, Inc.; Electrical Geodesics, Inc.; Medtronic; NeuroWave Systems, Inc.; Compumedics Ltd.; Noraxon U.S.A., Inc.; Cadwell Laboratories, Inc., and Nihon Kohden America, Inc.
b. Key factors that are driving the market growth include increasing prevalence of neurological disorders and rising awareness.
Avail customized purchase options to meet your exact research needs:
Get your queries resolved from an industry expert.
Design an exclusive study to serve your research needs.
A testimonial for service in the form of BBB "A" Accreditation.
Your personal and confidential information is safe and secure.
"The quality of research they have done for us has been excellent..."
With Covid-19 infections rising globally, the apprehension regarding a shortage of essential life-saving devices and other essential medical supplies in order to prevent the spread of this pandemic and provide optimum care to the infected also widens. In addition, till a pharmacological treatment is developed, ventilators act as a vital treatment preference for the COVID-19 patients, who may require critical care. Moreover, there is an urgent need for a rapid acceleration in the manufacturing process for a wide range of test-kits (antibody tests, self-administered, and others). The report will account for Covid19 as a key market contributor.